Company Overview: SGEN

Upcoming Projects (SGEN)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (SGEN)

Key Takeaways from ESMO 2023: A conversation with an oncologist attending the conference
Tickers: SGEN, MRK, NVS, MRTX, JNJ
Executed On: Nov 07, 2023 at 01:00 PM EST
Discussing the recent results from the phase 3 innovaTV 301 global trial, studying Genmab and Seagen's TIVDAK in recurrent or metastatic cervical cancer.
Tickers: SGEN, GMAB
Executed On: Sep 15, 2023 at 04:30 PM EDT
Digging into Seagen's Phase 2 Mountaineer trial (Tucatininb + Trastuzumab) for patients with HER2+ mCRC
Ticker: SGEN
Executed On: Jul 29, 2022 at 05:00 PM EDT
Digging into the PD-L1 ADC mechanism with a specific focus on SGN-PDL1V and MT-6402
Ticker: SGEN
Executed On: Mar 21, 2022 at 04:00 PM EDT

Expired Projects (SGEN)

Examining Tivdak (tisotumab vedotin) for recurrent or metastatic cervical cancer following chemotherapy progression
Ticker: SGEN
Execute By: Mar 31, 2022

Upcoming & Overdue Catalysts (SGEN)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (SGEN)

Astellas (ALPMY) and Seagen (SGEN) Announce Topline Results from Second Cohort of Patients in Phase 2 Pivotal Trial of PADCEV (enfortumab vedotin-ejfv) in Advanced Urothelial Cancer
Tickers: ALPMY, SGEN
Occurred on: Oct 12, 2020
Phase 1/2 initial data of Genmab's (GMAB) Enapotamab vedotin in Solid tumors to be presented at IASLC 2019 WCLC September 8, 2019
Tickers: GMAB, SGEN
Occurred on: Sep 08, 2019
Additional Analyses of Seattle Genetics'(SGEN) ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials of ADCETRIS (Brentuximab Vedotin) released at ASCO
Ticker: SGEN
Occurred on: Jun 03, 2019
Phase 3 data of ECHELON-1 trial of ADCETRIS in combination with chemotherapy for Frontline Hodgkin lymphoma due 2017
Ticker: SGEN
Occurred on: Jun 26, 2017
Seattle Genetics expected to report data in 2016 from a phase 1b trial of 33A in combination with cytarabine and daunorubicin for frontline, younger AML patients
Ticker: SGEN
Occurred on: Dec 03, 2016
Seattle Genetics (SGEN) Granted Breakthrough Therapy Status by FDA for Adcetris in Patients with CD30-Expressing Mycosis Fungoides (MF) and Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL)
Ticker: SGEN
Occurred on: Nov 10, 2016
Seattle Genetics Expects to Complete Enrollment in the Phase 3 ECHELON-2 Trial in Frontline Mature T-cell Lymphoma (MTCL) During 2016
Tickers: SGEN, TKPYY
Occurred on: Nov 08, 2016
Seattle Genetics Initiates Phase 1 Trial of SGN-CD123A for Patients with Relapsed or Refractory Acute Myeloid Leukemia
Ticker: SGEN
Occurred on: Sep 19, 2016
Phase 3 data of ALCANZA trial of ADCETRIS for relapsed CD30-positive cutaneous T-cell lymphoma due 2H 2016
Ticker: SGEN
Occurred on: Aug 01, 2016
Takeda and Seattle Genetics Announce Positive Data from Phase 3 ALCANZA Clinical Trial of ADCETRIS (Brentuximab Vedotin) for CD30-Expressing Cutaneous T-Cell Lymphoma
Tickers: TKPYY, SGEN
Occurred on: Aug 01, 2016
Seattle Genetics to report additional data from a Phase 1 trial of 33A in combination with HMAs at the European Hematology Association (EHA) annual meeting being held June 9 to 12, 2016 in Copenhagen, Denmark
Ticker: SGEN
Occurred on: Jun 11, 2016
Seattle Genetics to report phase 1 clinical data from ASG-15ME and ASG-22ME at the ASCO annual meeting being held June 3 to 7, 2016. These programs are in development in collaboration with Astellas for solid tumors, notably bladder cancer.
Tickers: SGEN, ALPMY
Occurred on: Jun 06, 2016
Phase 3 clinical trial to evaluate 33A in combination with HMAs in previously untreated older AML patients is planned to begin by the third quarter of 2016.
Ticker: SGEN
Occurred on: May 25, 2016
Seattle Genetics Initiates Phase 1/2 Trial of Vadastuximab Talirine (SGN-CD33A) Combination Therapy for Patients with Untreated Myelodysplastic Syndrome (MDS)
Ticker: SGEN
Occurred on: Feb 22, 2016
Seattle Genetics Announces Commercial and Regulatory Progress under ADCETRIS (Brentuximab Vedotin) Collaboration with Takeda
Tickers: SGEN, TKPYY
Occurred on: Feb 04, 2016

Strategic Initiatives (SGEN)

Seattle Genetics (SGEN) and Immunomedics (IMMU) Announce $2B License Deal for IMMU-132 in Triple-Negative Breast Cancer
Tickers: IMMU, SGEN
Announcement Date: Feb 10, 2017

SGEN Overview